SUO 2018: The Diagnosis, Management, and Screening of Lynch Syndrome
Phoenix, Arizona (UroToday.com) Lynch syndrome, also called hereditary non-polyposis colon cancer is described as an autosomal dominant germline mutation in one of several DNA mismatch repair genes. The DNA mismatch repair genes are protein complexes that repair DNA codon mismatches. They include MLH1, PMS2, MSH2, MSH6 (Figure 1).
SUO 2018: Three-year Renal Functional Outcomes of Patients Enrolled in the Intravenous Mannitol Versus Placebo During Partial Nephrectomy Randomized Controlled Trial
Phoenix, Arizona (UroToday.com) A previous prospective, randomized, double blind placebo controlled trial found that mannitol had no impact on renal function at 6 weeks and 6 months post operatively in patients with normal preoperative renal function undergoing partial nephrectomy. It had been hypothesized that mannitol may diminish reactive oxygen species that cause kidney damage. This abstract examined the 3 year long term renal functional outcomes of this previously presented study.
SUO 2018: Panel Discussion: Revisiting Cyroreductive Nephrectomy in the Current Era
Phoenix, Arizona (UroToday.com) This excellent multi-institutional and multidisciplinary panel was led by Dr. Margulis from University of Texas-Southwestern, where the current role of cytoreductive nephrectomy was discussed. To set the discussion into context, Dr. Margulis reviewed the 2001 SWOG New England Journal of Medicine and the 2001 EORTC Lancet prospective trials evaluating cytoreductive nephrectomy in the interferon era, where statistically significant survival benefits were seen in patients receiving cytoreductive nephrectomy.
SUO 2018: Neoadjuvant and Adjuvant Therapy: Current Guidelines and Practical Approach for the Urologic Surgeon
Phoenix, Arizona (UroToday.com) In this presentation Dr. Uzzo reviewed data in the neoadjuvant and adjuvant space for renal cell cancers. Prior to 2006, Dr. Uzzo stated that neoadjuvant and adjuvant therapies for high-risk kidney cancers largely did not exist. Although surgery remains incompletely effective, more effective systemic treatments have been developed.
SUO 2018: Topical Agents for Upper Tract Urothelial Carcinoma - How to Do It?
Phoenix, Arizona (UroToday.com) Upper tract urothelial carcinoma (UTUC) is associated with a worse prognosis than bladder UC, and while extirpative surgery is the mainstay of treatment for high grade and large volume disease, there has been an increase in utilization of endoscopic treatments over time particularly for low-grade tumors. European Association of Urology (EAU) 2017 guidelines advocate for categorization of UTUC into low and high-risk groups in order to guide treatment.
SUO 2018: Prospective Clinical Validation of a Molecular Urine Test For Detection Of High-grade Prostate Cancer
Phoenix, Arizona (UroToday.com) As our knowledge of prostate cancer (PCa) continues to grow, we have increasingly come to accept the fact that there is a subset of PCa that has little long-term clinical implications and can be watched – clinically insignificant prostate cancer, often Gleason 6 PCa (Gleason Grade Group 1). However, some Gleason Grade Group 2 cancers may also fit the bill. The rest of the PCa, as far as our current knowledge enables us to know, is clinically significant (csPCa) warranting treatment.
SUO 2018: Adjuvant Therapies in Kidney Cancer: FDA Panel Insights
Phoenix, Arizona (UroToday.com) Dr. Agrawal presented the findings of a recent FDA panel for adjuvant therapies in renal cell carcinoma. He reviewed workshop goals which included reviewing the eligibility criteria used for adjuvant RCC trials, radiographic eligibility, and definitions of disease recurrence in the absence of biopsy. Eligibility criteria are an important focus of the workshop particularly given significant variability in the number of recruits in individual trials depending on specific inclusion criteria.